Antiretroviral therapy in HIV

Journal Medical Libanais

Volumn 54, Issue 2, 2006, Pages 74-79

  Yu, Aimee ^a   Berbari, Elie ^a   Temesgen, Zelalem ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ASTHENIA; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DRUG DOSE REGIMEN; DRUG MECHANISM; FETUS MALFORMATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; INJECTION SITE ABSCESS; KIDNEY FAILURE; MORBIDITY; MORTALITY; MOUTH ULCER; NEPHROLITHIASIS; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PR INTERVAL; RASH; REVIEW; SIDE EFFECT; TASTE DISORDER; WEAKNESS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; WORLD HEALTH;

EID: 33750061056     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Young JAT. The replication cycle of HIV Type 1. In: PT Cohen, MA Sande, and PA Vollberding, editors. The AIDS Knowledge Base, Third edition. Philadelphia: Lippincott Williams & Wilkins, 1999.
2. Enfuvirtide [package insert]. Nutley, NJ: Roche Laboratories Inc., 2005.
3. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at http://www.aidsinfo.nih.gov. Updated electronically October 6, 2005.
4. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus Type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331 (18): 1173-80.
5. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Available at http://www.aidsinfo.nih.gov. Updated electronically November 17, 2005.
6. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997; 102 (suppl 5B): 9-15.
7. Ippolito G, Puro V, De Carli G, Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus in health care workers. Arch Int Med 1993; 153: 1451-8.
8. Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337: 1485-90.
9. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recommendations and Reports, 2001 June 29; 50 (No. RR-11): 1-42.
10. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other non-occupational exposure to HIV in the United States. MMWR 2005; 54 (No. RR-2): 1-20. Available at http://www.aidsinfo.nih. gov. Updated electronically January 21, 2005.